Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of G1T38 in Combination with Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer
2016-001485-29Phase 2Unknown
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Nov 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lerociclib in breast cancer, sponsored by G1 Therapeutics, Inc. Primary endpoints: Dose-limiting toxicities (DLTs) and Safety and tolerability. Status: unknown.
02
Drugs
lerociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-001485-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001485-29.